Finally, antibodies against EpCAM can efficiently target colorectal tumour-initiating cells [16], conferring a considerable value to the EpCAM-isolated CTC population in terms of therapeutic intervention. The gene discussed is EPCAM; the disease is colorectal neoplasm.